Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "bispecific"

48 News Found

Roche presents new data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022
Clinical Trials | December 12, 2022

Roche presents new data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022

Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes


LintonPharm to release data on Catumaxomab at ASCO meeting
Biotech | May 30, 2022

LintonPharm to release data on Catumaxomab at ASCO meeting

The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis


New data demonstrate clinical benefit of Roche’s glofitamab
Biotech | May 27, 2022

New data demonstrate clinical benefit of Roche’s glofitamab

Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma


Biocytogen signs RenMab/RenLite licensing agreement with BeiGene
Biotech | April 26, 2022

Biocytogen signs RenMab/RenLite licensing agreement with BeiGene

In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)


USFDA approves Genentech’s Vabysmo to treat causes of vision loss
Drug Approval | January 31, 2022

USFDA approves Genentech’s Vabysmo to treat causes of vision loss

Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need


ABL Bio collaborates with SANOFI for Parkinson’s antibody
Biotech | January 12, 2022

ABL Bio collaborates with SANOFI for Parkinson’s antibody

ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease


Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report
News | January 10, 2022

Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report

Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma


Exscientia and Sanofi collaborate for AI-driven precision-engineered medicine
Biotech | January 08, 2022

Exscientia and Sanofi collaborate for AI-driven precision-engineered medicine

Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties